Combination therapy of patients with locally advanced breast cancer

The investigation involved 30 patients with locally advanced breast cancer (T3-4N1-2M0). Combination therapy comprised two courses: carboplatin 300 mg/m2, i.v., dropwise, on day 1; doxorubicin 30 mg/m2, i.v., bolus-flow, on days 1 and 8; 5-fluorouracil 350 mg/m2, i.v., bolus-flow, on days 1 and 8, a...

Full description

Saved in:

Bibliographic Details
Published in:	Voprosy onkologij Vol. 47; no. 6; p. 740
Main Authors:	Manziuk, L V, Komov, D V, Khaĭlenko, V A, Artamonova, E V, Mikhina, Z P, Ermilova, V D, Abashin, S Iu
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 2001
Subjects:	Adult Antibiotics, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - administration & dosage Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - radiotherapy Breast Neoplasms - surgery Breast Neoplasms - therapy Carboplatin - administration & dosage Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - mortality Carcinoma, Ductal, Breast - radiotherapy Carcinoma, Ductal, Breast - surgery Carcinoma, Ductal, Breast - therapy Carcinoma, Lobular - drug therapy Carcinoma, Lobular - mortality Carcinoma, Lobular - radiotherapy Carcinoma, Lobular - surgery Carcinoma, Lobular - therapy Combined Modality Therapy Doxorubicin - administration & dosage Female Fluorouracil - administration & dosage Humans Mammography Mastectomy, Radical Middle Aged Radiotherapy Dosage Survival Analysis Time Factors
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The investigation involved 30 patients with locally advanced breast cancer (T3-4N1-2M0). Combination therapy comprised two courses: carboplatin 300 mg/m2, i.v., dropwise, on day 1; doxorubicin 30 mg/m2, i.v., bolus-flow, on days 1 and 8; 5-fluorouracil 350 mg/m2, i.v., bolus-flow, on days 1 and 8, and irradiation of the breast and regional metastasis area (single target dose--2 Gy, total target dose--40 Gy). Overall clinical response was 96.7% (29/30), mammography-wise--83.3% (25/30). All patients were found operable and radical mastectomy was performed in 25. Therapeutic effect stage III-IV was histologically confirmed in 40% (25/30), stage I-II--60% (15/25). Median overall and recurrence-free survival was not reached within 36 months in 24/30, relapse-free survival was been reported in 16/24 (66.6%), tumor progression--8/24 (33.4%). Three-year; host-mastectomy recurrence-free survival--68.8 +/- 16.0%.
ISSN:	0507-3758